データなし
データなし
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
Acurx Pharmaceuticals Analyst Ratings
Acurx Pharmaceuticals Shares Are Trading Higher After the Company Announced Its Preparing to Advance to Phase 3 Clinical Trials to Treat Patients With C. Difficile Infection.
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile Infection Based on Recent FDA and EMA Communications
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025